Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
1999 2
2000 1
2001 1
2003 1
2005 1
2006 4
2009 1
2010 1
2011 1
2012 3
2013 5
2014 5
2015 7
2016 2
2017 2
2018 1
2019 3
2020 4
2021 5
2022 7
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators. Fizazi K, et al. N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4. N Engl J Med. 2017. PMID: 28578607 Free article. Clinical Trial.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Motzer RJ, et al. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406148 Free PMC article. Clinical Trial.
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Oncogenic mechanisms in renal insufficiency.
Volovat SR, Volovat C, Miron I, Kanbay M, Goldsmith D, Lungulescu C, Badarau SC, Covic A. Volovat SR, et al. Among authors: volovat c. Clin Kidney J. 2020 Oct 23;14(2):507-515. doi: 10.1093/ckj/sfaa122. eCollection 2021 Feb. Clin Kidney J. 2020. PMID: 33623673 Free PMC article. Review.
Cisplatin and AKI: an ongoing battle with new perspectives-a narrative review.
Volovat S, Apetrii M, Stefan A, Vlad C, Voroneanu L, Hogas M, Haisan A, Volovat C, Hogas S. Volovat S, et al. Among authors: volovat c. Int Urol Nephrol. 2023 May;55(5):1205-1209. doi: 10.1007/s11255-022-03418-8. Epub 2022 Dec 12. Int Urol Nephrol. 2023. PMID: 36508071 Review.
The Landscape of Nanovectors for Modulation in Cancer Immunotherapy.
Volovat SR, Ursulescu CL, Moisii LG, Volovat C, Boboc D, Scripcariu D, Amurariti F, Stefanescu C, Stolniceanu CR, Agop M, Lungulescu C, Volovat CC. Volovat SR, et al. Among authors: volovat cc, volovat c. Pharmaceutics. 2022 Feb 11;14(2):397. doi: 10.3390/pharmaceutics14020397. Pharmaceutics. 2022. PMID: 35214129 Free PMC article. Review.
Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
Volovat SR, Scripcariu DV, Vasilache IA, Stolniceanu CR, Volovat C, Augustin IG, Volovat CC, Ostafe MR, Andreea-Voichița SG, Bejusca-Vieriu T, Lungulescu CV, Sur D, Boboc D. Volovat SR, et al. Among authors: volovat cc, volovat c. Int J Mol Sci. 2024 Jan 18;25(2):1180. doi: 10.3390/ijms25021180. Int J Mol Sci. 2024. PMID: 38256250 Free PMC article. Review.
Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review).
Volovat SR, Negru S, Stolniceanu CR, Volovat C, Lungulescu C, Scripcariu D, Cobzeanu BM, Stefanescu C, Grigorescu C, Augustin I, Lupascu Ursulescu C, Volovat CC. Volovat SR, et al. Among authors: volovat cc, volovat c. Exp Ther Med. 2021 May;21(5):535. doi: 10.3892/etm.2021.9967. Epub 2021 Mar 23. Exp Ther Med. 2021. PMID: 33815608 Free PMC article. Review.
61 results